Introduction
Left ventricular (LV) remodelling is a common finding in patients with advanced heart failure (HF) and reduced ejection fraction. 1 Previous studies have suggested a direct relationship between LV remodelling and outcomes in patients with HF, and interventions that have improved patients' outcomes are typically associated with substantial reverse remodelling. 2 A meta-analysis of studies has demonstrated a nearly linear association between LV reverse remodelling and outcomes, including survival or hospital readmission. 2 Multiple approaches have been proposed to ameliorate progressive maladaptive remodelling and to improve clinical outcomes of patients with advanced HF. Such therapies include angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), beta-blockers, and cardiac resynchronization therapy (CRT).
1,2 However, less is known about the impact of regenerative therapies on reverse remodelling. C3BS-CQR-1 is a cardiopoiesis-guided preparation of patient-derived mesenchymal stem cells (MSC) that has been proposed to potentially improve symptoms, functional capacity, and clinical outcomes in patients with advanced HF. 4 Specifically, C3BS-CQR-1 was first studied in humans in the Cardiopoietic Stem Cell Therapy in Heart Failure (C-CURE) clinical trial, 5 and subsequently underwent broader evaluation in the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study. 6, 7 In the CHART-1 study, the primary endpoint was not met despite observed trends in some of its components. As the effects of regenerative therapies, and especially stem-cell-based therapy, in HF are still largely unknown, many variables may influence efficacy. Among them, the number of injections may be an important factor as more injections may cause potential myocardial damage, through multiple mechanisms both mechanical and biological (such as inflammation). Indeed, a U-shaped dose-response relationship has recently been proposed in other stem cell therapy studies, with maximal efficacy achieved with a lower number of injections. 8 -11 This inverse dose response to MSC therapy in reducing LV volumes has been documented in the setting of clinical ischaemic cardiomyopathy, supporting the concept that excessive therapeutic intensity may offset benefit.
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The goals of the present post hoc analysis were to (i) examine the effect of cardiopoietic stem cell administration on LV remodelling (a component in the CHART-1 primary endpoint), and (ii) assess the modifying effect of cell dose/number of injections on the effectiveness of cardiopoietic cell therapy on remodelling indices at 52 weeks post-therapy.
Methods
The CHART-1 study was a randomized, controlled trial (clinicaltrials .gov NCT01768702, EudraCT 2011-001117-13) that evaluated the efficacy and safety of intramyocardial cardiopoietic stem cell (C3BS-CQR-1, Celyad S.A., Mont-Saint-Guibert, Belgium) administration for the treatment of advanced HF. The design and main study results have been previously reported. 6 HF secondary to ischaemic heart disease, reduced LV ejection fraction (LVEF <35%), and at high risk for recurrent HF-related events despite optimal medical therapy were eligible for the study. Patients provided written, informed consent before study-specific procedures, and the study was approved by the ethics committee at each participating centre. Of 484 patients screened, 348 patients underwent bone marrow harvest (see Supplementary material online, Figure S1 ). In 315 patients, successful MSC expansion was achieved, followed by 1:1 randomization to receive either injection of up to 600×10 6 lineage-directed cardiopoietic stem cells (n=157) or a sham procedure (n=158). The sham procedure involved introduction of an introducer sheath, LV angiography, and pigtail catheter movements but no injections. For those patients who received active treatment, a frozen preparation of cardiopoietic cells was reconstituted on site to a concentration of 57-60x10 6 cells/mL, and delivered via a retention-enhanced catheter (C-Cathez ® , Celyad S.A.) in up to twenty 0.5-mL injections spaced ∼1 cm apart over the left ventricle where wall thickness was at least 8 mm and avoiding the apex and non-basal portion of the septum. A total of 271 patients underwent the procedure to which they were randomized: 120 patients who received cardiopoietic cell injections and 151 patients who underwent a sham procedure. Patients who died or withdrew consent without having either procedure, and patients assigned to active treatment who were no longer eligible for the procedure or whose cardiopoietic cells did not meet release criteria were excluded. Patients and assessing investigators were blinded to the study treatment assignment.
Echocardiography
Standard two-dimensional transthoracic echocardiography using harmonic mode imaging was performed at screening, baseline (within 1 week prior to the study procedure) and at weeks 26, 39, and 52 post-procedure. Images were obtained by qualified sonographers trained on the imaging protocol and using common image acquisition guidelines. Screening echocardiograms were read locally for echocardiographic inclusion criteria (LVEF and LV wall thickness), and the remaining echocardiograms were read by a blinded, imaging core laboratory (Bioclinica ® , Princeton, NJ, USA). Subjects who were difficult to image, had views difficult to reproduce serially, or for whom a high-quality echocardiogram could not be obtained at screening were not enrolled in the study.
Core laboratory readers measured LV areas from apical two-and four-chamber views, and LV volumes were calculated using Simpson's biplane method of disks summation; LVEF was calculated from LV end-diastolic volume (LVEDV) and LV end-systolic volume (LVESV). Left ventricular mass was estimated from two-dimensional images using the 2D Teichholz method from parasternal long-axis view measurements of the interventricular septum, LV internal diameter, and LV posterior wall thickness at end-diastole.
Statistical analysis
Unadjusted analyses are based on available data. Cox regression models were used to estimate the associations between baseline values of LVEDV, LVESV, LVEF, and LV mass with clinical outcomes; time to HF hospitalization was censored at the time of death for this analysis. Changes from baseline to week 52 in each echocardiographic measure were compared between treatment groups using two-sample t-tests.
A multivariable linear regression model prognostic of LVEDV change from baseline to week 52 was developed from covariates found in HRs for the given outcome associated with the given increment in the echocardiographic parameter are presented. CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction; LVM, left ventricular mass. models previously established to be prognostic in chronic HF 13 -15 and available within the CHART-1 database. To address the concern that the apparently larger effect of cardiopoietic cell therapy in patients with more severe HF 7 might mask associations with baseline variables, the multivariable model was developed in the sham control group. The linearity of associations with continuous predictors was assessed by testing the non-linear contribution to a restricted cubic spline transformation, and through visual inspection of observed mean changes in quintiles of the continuous predictor. visual inspection of the plots. Ten multiple imputation datasets employing an imputation method based on multivariate normality 16 were used to handle missing predictor values. Backwards selection with a criterion for inclusion of P<0.10 was applied to each multiple imputation dataset, and the final model included covariates selected in the majority of the imputation datasets. Parameter estimates and significance tests were obtained by averaging the final model over the imputation datasets using Rubin's rule. 17 The effect of cardiopoietic cell treatment on LVEDV change was then estimated by including patients in both treatment groups and adjusting for those covariates included in the final model. The effect of cardiopoietic cell treatment as a function of the number of injections was assessed. As the frozen cell product contained a given number of cardiopoietic cells (0.6x10 9 cells), which was reconstituted to a specified volume (13±1 mL) of ready-to-use suspension and then administered in injections of fixed volume per injection (0.5 mL), the actual number of cells injected per subject was closely correlated with the number of injections (r=0.9735) and with the total volume administered (r=0.9754). Accordingly, the effects of number of injections, volume injected, and number of cells injected are inextricably correlated and proportional such that an analysis by number of cells injected mirrors the analysis by number of injections. Hence, we analysed the effect of 'more' versus 'less' therapy on remodelling measures using the number of cardiopoietic cell injections, with patients grouped by approximates of tertiles. Baseline characteristics are presented in these groups, and changes in LV measures in each tertile group are compared with control using two-sample t-tests. The multivariable-adjusted effect of number of injections on LVEDV change from baseline was evaluated by including number of injections as a continuous measure in the multivariable model for LVEDV change from baseline (all controls received zero injections) in the place of treatment group. Two-sided P-values <0.05 were considered statistically significant without adjustment for multiple comparisons. Analyses were performed using SAS ® version 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Of the 271 patients who received the randomized study procedure, 268 (98.9%) had an available baseline echocardiogram; LV volumes could be measured in 254 (93.7%) patients at baseline. The number of patients with evaluable measures at each time point is given in Figure 1 . The proportion of patients missing the follow-up -either due to death or other reason -was largely similar in the two groups. At week 52, 16 (13.3%) active versus 18 (12.0%) sham patients were missing the LVEDV value due to death or LV assist device implantation (which was handled as a death for analysis) while 2 (1.7%) active versus 5 (3.3%) sham patients were missing the value due to other reasons. LVEDV and LVESV decreased significantly more in the active arm than in controls (Figure 1) . At 52 weeks, LVEDV decreased by a mean of 17.0 mL (95% confidence interval -28.9, -5.0) more in the cardiopoietic cell-treated patients compared to controls (P=0.006) and LVESV decreased by 12.8 mL (95% confidence interval -23.4, -2.3) more in the cardiopoietic cell-treated patients compared to controls (P=0.017). There were no differences between treatment groups overall with respect to changes in LVEF and LV mass.
Univariable and multivariable predictors of 1-year change in LVEDV in the sham control group are presented in Table 2 . The variables associated independently with LVEDV change included age, baseline systolic blood pressure, history of myocardial infarction and baseline LVEDV and LVEF. Older age, history of myocardial infarction and baseline LVEDV were all inversely associated with the change in LVEDV. Baseline systolic blood pressure had a non-linear, U-shaped association with LVEDV change, while baseline LVEF had an umbrella-shaped association. After multivariable correction for these covariates, the association of cardiopoietic cell treatment with 1-year LVEDV change was of borderline significance (P=0.0545) ( Table 3) .
While very few patients (n=3, 2.5%) received 21 injections, most received the maximum number of injections allowed per protocol (20 injections, n=53, 44.2%), followed by 19 (n=17, 14.2%), 18 (n=12, 10.0%), 17 (n=6, 5.0%), 16 (n=6, 5.0%), and 15 (n=11, 9.2%) injections; the remaining 12 patients (10.0%) received 14 or fewer injections. Baseline characteristics by number of injections administered, grouped by approximate tertiles, are described in Table 4 . There were no significant baseline differences between groups with respect to the number of injections although time from HF diagnosis, ventricular arrhythmias, defibrillator implant, CRT, and renal impairment were numerically different between groups. The mean changes in LVEDV, LVESV, LVEF and LV mass in the sham control group and cardiopoietic cell group divided by number of injections are depicted in Figure 2 . Compared with controls, significant reductions in LVEDV and LVESV and a trend towards reductions in LV mass were observed in patients administered the fewest injections (≤20), with a tendency towards reduced effects in patients administered higher (n=56)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . numbers of injections (see Supplementary material online, Table  S1 ). Linear regression modelling suggests a U-shaped association between the number of cardiopoietic cell injections (with sham patients receiving zero injections) and LVEDV change, which remained statistically significant after multivariable adjustment ( Table 5 ).
Discussion
The echocardiographic results of the CHART-1 study at 52 weeks suggest that intramyocardial administration of cardiopoietic stem cells (C3BS-CQR-1) has a beneficial effect on LV remodelling, both on LVEDV and LVESV, during a 52-week follow-up. The magnitude of the decrease in LV volumes compares favourably with the effects of beta-blockers, renin-angiotensin-aldosterone system blockers and CRT on ventricular remodelling, 18 -25 an effect that has been consistently associated with improved long-term outcomes in larger studies. where the vast majority of patients were treated with ACEi or ARBs, beta-blockers and CRT where applicable. 6 These effects were maintained even after multivariable adjustment for the baseline characteristics found in the present study to affect the 52-week LVEDV change (Tables 2, 3 and 5) . In contrast to the above-mentioned interventions, intramyocardial cardiopoietic cell administration did not improve LVEF or LV mass overall, although significant effects were observed in patients receiving fewer injections (see below).
Several recent studies have suggested that there may be a ceiling effect regarding the number of intramyocardial injections administered in cell therapy studies. 8 -12 In an exploratory, post hoc analysis, we observed decreased efficacy in patients administered a high number (≥20) of injections and increased benefit in patients administered a moderate number of injections. The present analysis suggests that decreases in LVEDV and LVESV are associated with the delivery of cells using a lower number of injections as compared to sham controls and those treated with more injections (Figure 2) , while LVEF and LV mass did not improve significantly. The reason for such interaction is likely multi-factorial. A higher number of injections may induce myocardial damage leading to reduced efficacy. This may be related to trauma from the injections themselves, the volume injected or possibly the number of cells delivered.
11,12
Although in the current study troponin levels tended to be higher in patients administered more injections at 24 hours and 9 months from the procedure (unpublished data), no further troponin measurements were performed limiting the ability to correlate troponin leaks and treatment effect. Furthermore, in the CHART-1 study, a novel catheter (C-Cathez ® ) was utilized for the intramyocardial administration of cardiopoietic cells. Proof-of-concept studies have documented that this catheter administration system achieves a higher retention of injected cells. 26 
Limitations
The current analysis is a post hoc analysis of the CHART-1 study and as such any conclusions should be viewed as hypothesis-generating and subject to confirmation. Patients who died did not have echocardiography follow-up; however, the number of deaths was largely similar in the active and sham group. 7 The description of treatment effects by number of injections lacks a robust control, because the sham procedure patients did not receive injections and hence no real comparator with respect to the number of injections can be identified within the sham-exposed patients. Furthermore, the absolute number of patients in the lowest injection tertile was small, raising the possibility that the findings were a play of chance, dictated by other factors, influenced by the cumulative effect of important but non-significant 
Conclusion
This is a post hoc evaluation of the CHART-1 study. The CHART-1 study is the largest stem cell trial to date addressing the effect of intramyocardial administration of cardiopoietic stem cells in patients with advanced ischaemic HF. In this at-risk population with limited therapeutic options, cardiopoietic stem cell therapy showed significant reverse remodelling effects with an improvement in LV volumes, especially in the subgroup of patients who received a moderate number of injections. Further studies are needed to explore the relationship between number of intramyocardial injections, number of cardiopoietic stem cells and volume administered and their impact on the observed reverse remodelling outcome.
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